Paladin Labs
Jean De Serres has extensive experience in the biopharmaceutical industry, holding various positions in multiple organizations. Jean currently serves as a member of the Board of Directors for Fonds de solidarité FTQ and Altus Drug Development since 2022. From 2014 to the present, they have been the VP of Scientific Affairs and Operations at Paladin Labs. In 2003, they co-founded Med-Discovery and also co-founded Biomilestones in 2007. Jean De Serres served as a Board Member for Feldan Bio from 2015 until June 2023. Jean was also a member of the Board of Directors for Cadens from 2012 to November 2016, Montreal invivo in 2014, and Héma-Québec from April 2011 to October 2014, where they also held the position of CEO during that period. In addition, Jean De Serres worked independently as "The Rise of the Unicorn" from February 2018 to December 2020.
Jean De Serres has a diverse education history. In 1979, they obtained their MD degree in Medicine from Université de Montréal. Following this, they pursued a Certificate in Epidemiology from IDEA-CDC, which they completed in an unspecified year. From 1997 to 2002, Jean studied Public Health and obtained an M.Sc degree from Université de Montréal. In 2001 to 2003, they attended the University of Quebec, where they obtained a Certificate in Administration. During the same period, they also pursued an MBA in Biopharma from École des sciences de la gestion (ESG UQAM). Continuing with their education in Corporate Governance, Jean attended the ICD / IAS Institute of Corporate Directors in 2012 to obtain the Institute of corporate directors (ICD) degree. Additionally, they have obtained a certification from the Institute of Corporate Directors (ICD/IAS), but the specific date of completion is unknown. The information about their education at Séminaire de Joliette is not available.
This person is not in any offices
Paladin Labs
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. Paladin has a focused marketing and sales organization that has helped it evolve into a well-known Canadian specialty pharmaceutical company with a breadth of products. Paladin is an operating company of Endo International plc (NASDAQ: ENDP), a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients through excellence in development, manufacturing and commercialization.